The Oncomine Dx Express Test for oncology biomarker profiling

A patient’s tumor profile has the potential to guide precision oncology care, but only if the results are reported in time. Now, with the Ion Torrent™ Oncomine™ Dx Express Test on the Ion Torrent™ Genexus™ System*, you can perform fast NGS testing for clinically relevant biomarkers in as little as 24 hours.

The time to informed treatment decisions is critical for oncology patients. Automation and ease of use are key to enabling implementation of NGS workflows in every laboratory.

Patients everywhere should be routinely tested for clinically relevant biomarkers.

Even small biopsies should generate results.

EGFR

KRAS

ROS1

<24

as little as 24 hours

turnaround time from sample to clinically relevant biomarker report

Patients everywhere should be routinely tested for clinically relevant biomarkers.

46 genes including EGFR, ALK, BRAF, ROS1, RET, KRAS, FGFR3, NTRK, MET, IDH1 and ERBB2, among others

100% clinically relevant biomarkers for NSCLC and majority for other solid tumors1, 2

Automation and ease of use are key to enabling implementation of NGS workflows in every laboratory.

Even small biopsies should generate results.

10 ng

minimum sample input

~95%

sample success rate

1 supplier and team to support you

2 instruments* 1 software and report linking biomarkers with relevant evidence from approved therapies, guidelines, and clinical trials

2 touchpoints 20 minutes hands-on time

© 2022 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. The content provided herein may relate to products that have not been officially released and is subject to change without notice.

100% clinically relevant biomarkers = unique biomarkers that have an ESCAT level of IA, IB, or IC; majority = 86%, BRCA1/2 and MSI-H are not covered by the Oncomine Dx Express Test.


https://www.oncomine.com/express-test

* The content provided herein may relate to products or workflows that have not been officially released or fully validated and is subject to change without notice.